Cargando…
Stat3 as a potential therapeutic target for rheumatoid arthritis
Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain u...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591217/ https://www.ncbi.nlm.nih.gov/pubmed/28887478 http://dx.doi.org/10.1038/s41598-017-11233-w |
_version_ | 1783262666564829184 |
---|---|
author | Oike, Takatsugu Sato, Yuiko Kobayashi, Tami Miyamoto, Kana Nakamura, Satoshi Kaneko, Yosuke Kobayashi, Shu Harato, Kengo Saya, Hideyuki Matsumoto, Morio Nakamura, Masaya Niki, Yasuo Miyamoto, Takeshi |
author_facet | Oike, Takatsugu Sato, Yuiko Kobayashi, Tami Miyamoto, Kana Nakamura, Satoshi Kaneko, Yosuke Kobayashi, Shu Harato, Kengo Saya, Hideyuki Matsumoto, Morio Nakamura, Masaya Niki, Yasuo Miyamoto, Takeshi |
author_sort | Oike, Takatsugu |
collection | PubMed |
description | Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain unclear and targeted therapy for this condition has not been established. Here, we provide evidence that signal transducer and activator of transcription 3 (Stat3) promotes inflammation and joint erosion in a mouse model of arthritis. Stat3 global KO mice show early embryonic lethality; thus, we generated viable Stat3 conditional knockout adult mice and found that they were significantly resistant to collagen-induced arthritis (CIA), the most common RA model, compared with controls. We then used an in vitro culture system to screen ninety-six existing drugs to select Stat3 inhibitors and selected five candidate inhibitors. Among them, three significantly inhibited development of arthritis and joint erosion in CIA wild-type mice. These findings suggest that Stat3 inhibitors may serve as promising drugs for RA therapy. |
format | Online Article Text |
id | pubmed-5591217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55912172017-09-13 Stat3 as a potential therapeutic target for rheumatoid arthritis Oike, Takatsugu Sato, Yuiko Kobayashi, Tami Miyamoto, Kana Nakamura, Satoshi Kaneko, Yosuke Kobayashi, Shu Harato, Kengo Saya, Hideyuki Matsumoto, Morio Nakamura, Masaya Niki, Yasuo Miyamoto, Takeshi Sci Rep Article Rheumatoid arthritis (RA) is a multi-factorial disease characterized by chronic inflammation and destruction of multiple joints. To date, various biologic treatments for RA such as anti-tumor necrosis factor alpha antibodies have been developed; however, mechanisms underlying RA development remain unclear and targeted therapy for this condition has not been established. Here, we provide evidence that signal transducer and activator of transcription 3 (Stat3) promotes inflammation and joint erosion in a mouse model of arthritis. Stat3 global KO mice show early embryonic lethality; thus, we generated viable Stat3 conditional knockout adult mice and found that they were significantly resistant to collagen-induced arthritis (CIA), the most common RA model, compared with controls. We then used an in vitro culture system to screen ninety-six existing drugs to select Stat3 inhibitors and selected five candidate inhibitors. Among them, three significantly inhibited development of arthritis and joint erosion in CIA wild-type mice. These findings suggest that Stat3 inhibitors may serve as promising drugs for RA therapy. Nature Publishing Group UK 2017-09-08 /pmc/articles/PMC5591217/ /pubmed/28887478 http://dx.doi.org/10.1038/s41598-017-11233-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Oike, Takatsugu Sato, Yuiko Kobayashi, Tami Miyamoto, Kana Nakamura, Satoshi Kaneko, Yosuke Kobayashi, Shu Harato, Kengo Saya, Hideyuki Matsumoto, Morio Nakamura, Masaya Niki, Yasuo Miyamoto, Takeshi Stat3 as a potential therapeutic target for rheumatoid arthritis |
title | Stat3 as a potential therapeutic target for rheumatoid arthritis |
title_full | Stat3 as a potential therapeutic target for rheumatoid arthritis |
title_fullStr | Stat3 as a potential therapeutic target for rheumatoid arthritis |
title_full_unstemmed | Stat3 as a potential therapeutic target for rheumatoid arthritis |
title_short | Stat3 as a potential therapeutic target for rheumatoid arthritis |
title_sort | stat3 as a potential therapeutic target for rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591217/ https://www.ncbi.nlm.nih.gov/pubmed/28887478 http://dx.doi.org/10.1038/s41598-017-11233-w |
work_keys_str_mv | AT oiketakatsugu stat3asapotentialtherapeutictargetforrheumatoidarthritis AT satoyuiko stat3asapotentialtherapeutictargetforrheumatoidarthritis AT kobayashitami stat3asapotentialtherapeutictargetforrheumatoidarthritis AT miyamotokana stat3asapotentialtherapeutictargetforrheumatoidarthritis AT nakamurasatoshi stat3asapotentialtherapeutictargetforrheumatoidarthritis AT kanekoyosuke stat3asapotentialtherapeutictargetforrheumatoidarthritis AT kobayashishu stat3asapotentialtherapeutictargetforrheumatoidarthritis AT haratokengo stat3asapotentialtherapeutictargetforrheumatoidarthritis AT sayahideyuki stat3asapotentialtherapeutictargetforrheumatoidarthritis AT matsumotomorio stat3asapotentialtherapeutictargetforrheumatoidarthritis AT nakamuramasaya stat3asapotentialtherapeutictargetforrheumatoidarthritis AT nikiyasuo stat3asapotentialtherapeutictargetforrheumatoidarthritis AT miyamototakeshi stat3asapotentialtherapeutictargetforrheumatoidarthritis |